earnings
NR
NASDAQ · NRIX
Nurix Therapeutics, Inc.
Healthcare · Biotechnology
$26.26
Down-$0.61 (-2.32%)
Updated Sep 10, 2026, 1:55 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.47B
- P/E ratio
- -6.56
- Dividend yield
- 0.00%
- 52-week range
- $8.20 – $28.23
- Volume
- 1.03M
- Avg. volume
- 1.68M
Price performance
NRIX price history
1M range · 20 trading sessions · Daily adjusted prices
NRIX closed at $26.26 after 20 trading sessions, down 1.39% for the selected period.
- Last close
- $26.26
- Period change
- -1.39%
- Period low
- $25.32
- Period high
- $27.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $26.46 | $26.695 | $25.91 | $26.26 | 1.03M |
| Sep 8, 2026 | $25.42 | $26.42 | $25.36 | $26.13 | 1.29M |
| Sep 4, 2026 | $25.19 | $26.22 | $24.97 | $26.14 | 1.23M |
| Sep 3, 2026 | $25.82 | $26.16 | $24.95 | $25.32 | 1.38M |
| Sep 2, 2026 | $26.35 | $26.915 | $25.39 | $25.82 | 1.74M |
| Sep 1, 2026 | $25.47 | $26.11 | $25.47 | $26.04 | 1.6M |
| Aug 31, 2026 | $26.00 | $26.23 | $25.17 | $25.78 | 1.24M |
| Aug 28, 2026 | $26.52 | $26.87 | $26.125 | $26.21 | 929.23K |
| Aug 27, 2026 | $26.795 | $27.50 | $26.235 | $26.875 | 1.26M |
| Aug 26, 2026 | $26.77 | $27.23 | $26.44 | $26.71 | 551.88K |
| Aug 25, 2026 | $26.72 | $27.38 | $26.378 | $26.95 | 1.18M |
| Aug 24, 2026 | $26.37 | $26.685 | $25.86 | $26.27 | 874.21K |
| Aug 21, 2026 | $27.41 | $27.50 | $26.70 | $26.72 | 1.49M |
| Aug 20, 2026 | $27.33 | $27.565 | $26.6792 | $27.05 | 1.09M |
| Aug 19, 2026 | $27.50 | $28.23 | $27.015 | $27.79 | 2.1M |
| Aug 18, 2026 | $26.51 | $27.04 | $26.51 | $26.93 | 816.02K |
| Aug 17, 2026 | $26.62 | $27.22 | $26.50 | $27.17 | 1.15M |
| Aug 14, 2026 | $27.01 | $27.245 | $26.19 | $27.05 | 738.5K |
| Aug 13, 2026 | $26.92 | $27.35 | $26.44 | $27.19 | 1.37M |
| Aug 12, 2026 | $25.95 | $26.82 | $25.775 | $26.63 | 912.79K |
Latest NRIX news
The latest Smart Investors Daily articles mentioning NRIX.
Stock researchResearch & News · SEC Filings
Loading stock research…